Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Is Getting Increasingly Hard To Ignore
Currently, there are 255.94M common shares owned by the public and among those 226.52M shares have been available to trade. The company’s stock has a 5-day price change of -16.67% and -56.60% over the past three months. ADAP shares are trading -53.59% year to date (YTD), with the 12-month market performance down to -78.07% lower. […]
Adaptimmune Therapeutics Plc ADR (ADAP) Outlook Starting To Look Brighter?
Adaptimmune Therapeutics Plc ADR (ADAP) concluded trading on Wednesday at a closing price of $0.31, with 6.75 million shares of worth about $2.09 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -67.91% during that period and on April 03, 2025 the price saw […]
Growth Story Still Intact For Adaptimmune Therapeutics Plc ADR (ADAP)
Adaptimmune Therapeutics Plc ADR (ADAP) concluded trading on Thursday at a closing price of $0.28, with 13.94 million shares of worth about $3.9 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -73.33% during that period and on March 20, 2025 the price saw […]
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) – Suitable For Long Term Buy?
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling […]
